Recommendations from primary care physicians, family, friends and work colleagues influence patients' decisions related to hepatitis screening, medical examinations and antiviral treatment

Okada,Michiaki; Oeda,Satoshi; Katsuki,Naoko; Iwane,Shinji; Kawaguchi,Yasunori; Kawamoto,Saori; Tomine,Yoshimi; Fukuyoshi,Jun; Maeyama,Keishiro; Tanaka,Hideo; Anzai,Keizo; Eguchi,Yuichiro

doi:10.3892/etm.2020.8533

Recommendations from primary care physicians, family, friends and work colleagues influence patients' decisions related to hepatitis screening, medical examinations and antiviral treatment

Authors:
- Michiaki Okada
- Satoshi Oeda
- Naoko Katsuki
- Shinji Iwane
- Yasunori Kawaguchi
- Saori Kawamoto
- Yoshimi Tomine
- Jun Fukuyoshi
- Keishiro Maeyama
- Hideo Tanaka
- Keizo Anzai
- Yuichiro Eguchi
View Affiliations

Affiliations: Department of Internal Medicine, Faculty of Medicine, Saga University, Saga‑Shi, Saga 849‑8501, Japan, Liver Center, Saga University Hospital, Saga‑Shi, Saga 849‑8501, Japan, Department of General Medicine, Saga University Hospital, Saga‑Shi, Saga 849‑8501, Japan, Cancer Scan, Tokyo 141‑0031, Japan, Division of Epidemiology and Prevention, Aichi Cancer Center, Nagoya, Aichi 464‑8681, Japan
Published online on: February 18, 2020 https://doi.org/10.3892/etm.2020.8533
Pages: 2973-2982
Copyright: © Okada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification and screening of patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) is important to prevent liver cancer. Comprehensive antiviral treatments should follow three sequential steps: Hepatitis screening (step 1; examination of HB surface antigen and HCV antibody), medical examination (step 2; examination of HBV‑DNA and/or HCV‑RNA and performance of abdominal ultrasonography) and antiviral treatment (step 3). Patients who underwent these three steps were studied to determine effective information sources (factors) for raising awareness of comprehensive treatments. A total of 182 patients from 11 medical institutions were who were undergoing antiviral treatment were investigated. The number of patients who accessed each of the 18 information sources in each of the three steps and the percentage of these information sources that directly influenced the participants to make treatment‑related decisions were calculated. ‘Recommendation from a primary care physician’ was the most common information source (64.3, 77.5, and 75.8% at steps 1, 2, and 3, respectively). ‘Recommendation from a public health nurse (PHN),’ ‘recommendation from friends or family,’ and ‘recommendation from work colleagues’ were the next most common human factors (3.3‑19.8%). ‘Recommendation from a primary care physician’ had the greatest influence (76.9, 73.0, and 77.5% at steps 1, 2, and 3, respectively). ‘Recommendation from a PHN’ (50.0, 26.3 and 64.3%), ‘recommendations from friends and family’ (58.3, 38.9 and 58.3%), and ‘recommendations from work colleagues’ (33.3, 33.3 and 42.9%) were highly influential factors. Media such as TV commercial messages and programs also had high recognition, but were not directly influential. The findings of the present study indicated that recommendations from primary care physicians, friends, family and work colleagues influenced patients' decision‑making regarding hepatitis screening, examination and treatment.

View Figures

View References

1	Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, et al: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology. 12:671–675. 1990.PubMed/NCBI View Article : Google Scholar
2	Fattovich G, Bortolotti F and Donato F: Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol. 48:335–352. 2008.PubMed/NCBI View Article : Google Scholar
3	Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 350:1118–1129. 2004.PubMed/NCBI View Article : Google Scholar
4	Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, et al: Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 52:652–657. 2010.PubMed/NCBI View Article : Google Scholar
5	Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H and Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 29:1124–1130. 1999.PubMed/NCBI View Article : Google Scholar
6	Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, et al: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 27:1394–1402. 1998.PubMed/NCBI View Article : Google Scholar
7	Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
8	Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskala E, Brainard DM, Symonds WT, et al: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 370:1993–2001. 2014.PubMed/NCBI View Article : Google Scholar
9	Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomes M, Zarski JP, Agarwal K, Buggisch P, et al: Ledipasvir and sofosbuvir for untreated HCVgenotype 1 infection. N Engl J Med. 370:1889–1898. 2014.PubMed/NCBI View Article : Google Scholar
10	Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, et al: Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 370:1594–1603. 2014.PubMed/NCBI View Article : Google Scholar
11	Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P and Popescu M: Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis. B Hepatol Int. 2:102–110. 2008.PubMed/NCBI View Article : Google Scholar
12	Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, et al: Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 57:508–514. 2012.PubMed/NCBI View Article : Google Scholar
13	Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 58:1537–1547. 2013.PubMed/NCBI View Article : Google Scholar
14	Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, et al: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 359:2442–2455. 2008.PubMed/NCBI View Article : Google Scholar
15	Eguchi Y, Maeyama K, Ozaki I and Hrai K: Medical system for liver disease treatment in response to basic act on hepatitis measures. Nihon Naikagakkai Zasshi. 103:11–18. 2014.(In Japanese). PubMed/NCBI View Article : Google Scholar
16	SagaPrefectural Government: Saga Liver Disease Measures promotion Plan (In Japanese). Available at: http://www.pref.saga.lg.jp/kiji00334103/3_34103_1_20134893825.pdf. Accessed January 15, 2017.
17	Ministry of Health, Labor and Welfare, Japan. Investigation Committee for blood business sectional meeting security technology 2011 first (In Japanese) Available at: http://www.mhlw.go.jp/stf/shingi/2r98520000020hlt.html. Accessed January 15, 2017.
18	Cancer Information and Service National Cancer Center Japan. Cancer Registry and Statistics (In Japanese). Available at: http://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed January 15, 2017.
19	Tateno Y, Miyazaki Y, Tsuboi S and Uehara R: Can screening invitations from primary care physicians increase participation in cancer screenings on remote islands? General Medicine. 14:40–47. 2013.
20	Lacaille D and Pam R: Why are people with rheumatoid arthritis (RA) not using DMARDs? Understanding gaps in care. J Rheumatol. 46(1218)2008.
21	Penson DF: Factors influencing patients' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr. 2012:207–212. 2012.PubMed/NCBI View Article : Google Scholar
22	McAllister KA and Schmitt ML: Impact of a nurse navigator on genomic testing and timely treatment decision making in patients with breast cancer. Clin J Oncol Nurs. 19:510–512. 2015.PubMed/NCBI View Article : Google Scholar